Abstract:While the mainstay of acute stroke treatment includes revascularization via recombinant tissue plasminogen activator or mechanical thrombectomy, only a minority of stroke patients are eligible for treatment, as delayed treatment can lead to worsened outcome. This worsened outcome at the experimental level has been attributed to an entity known as reperfusion injury (R/I). R/I is occurred when revascularization is delayed after critical brain and vascular injury has occurred, so that when oxygenated blood is restored, ischemic damage is increased, rather than decreased. R/I can increase lesion size and also worsen blood barrier breakdown and lead to brain edema and hemorrhage. A major mechanism underlying R/I is that of poststroke inflammation. The poststroke immune response consists of the aberrant activation of glial cell, infiltration of peripheral leukocytes, and the release of damage-associated molecular pattern (DAMP) molecules elaborated by ischemic cells of the brain. Inflammatory mediators involved in this response include cytokines, chemokines, adhesion molecules, and several immune molecule effectors such as matrix metalloproteinases-9, inducible nitric oxide synthase, nitric oxide, and reactive oxygen species. Several experimental studies over the years have characterized these molecules and have shown that their inhibition improves neurological outcome. Yet, numerous clinical studies failed to demonstrate any positive outcomes in stroke patients. However, many of these clinical trials were carried out before the routine use of revascularization therapies. In this review, we cover mechanisms of inflammation involved in R/I, therapeutic targets, and relevant experimental and clinical studies, which might stimulate renewed interest in designing clinical trials to specifically target R/I. We propose that by targeting anti-inflammatory targets in R/I as a combined therapy, it may be possible to further improve outcomes from pharmacological thrombolysis or mechanical thrombectomy.

The role of neuro-inflammatory in the pathogenesis of brain edema and hemorrhagic transformation in ischemic stroke: mechanisms and therapeutic target

Systemic immune responses after ischemic stroke: From the center to the periphery

Neuroinflammation in Acute Ischemic and Hemorrhagic Stroke

Inflammatory Responses in Brain Ischemia

Inflammatory mechanisms in ischemic stroke: therapeutic approaches

Neuroinflammation in Cerebral Ischemia and Ischemia/Reperfusion Injuries: From Pathophysiology to Therapeutic Strategies

MicroRNAs Modulate Neuroinflammation after Intracerebral Hemorrhage: Prospects for New Therapy.

Pathogenetic scenarios of the development of brain ischemia and the main elements of the ischemic cascade

Mechanism and Therapy of Brain Edema after Intracerebral Hemorrhage.

Neuroinflammation after Intracerebral Hemorrhage and Potential Therapeutic Targets

Potential therapeutic targets for intracerebral hemorrhage-associated inflammation: An update

Anti-Inflammatory Targets for the Treatment of Reperfusion Injury in Stroke

Neuroinflammatory Mechanisms in Ischemic Stroke: Focus on Cardioembolic Stroke, Background, and Therapeutic Approaches

Neuroinflammatory mechanisms of blood-brain barrier damage in ischemic stroke

Emerging therapeutic targets associated with the immune system in patients with intracerebral haemorrhage (ICH): From mechanisms to translation

Dynamic inflammatory changes of the neurovascular units after ischemic stroke.

Secondary mechanisms of injury and viable pathophysiological targets in intracerebral hemorrhage

The hallmark and crosstalk of immune cells after intracerebral hemorrhage: Immunotherapy perspectives

Reperfusion injury after focal cerebral ischemia: the role of inflammation and the therapeutic horizon